RIGI and pancreatic neoplasm: Intratumoral delivery of RIG‐I agonists induces apoptosis of pancreatic cancer cells in a type I IFN‐dependent manner and enhances effective cross‐presentation of tumour‐associated antigens by dendritic cells to CD8+ T cells, therefore leading to tumour regression and prolonged survival of mice bearing pancreatic cancer (Duewell et al., 2014).